Kornimate/medical-research-clean huggingface dataset:
hysteroscopic injections of autologous endometrial cells and platelet-rich plasma in patients with thin endometrium

Conditions: Thin Endometrium

Summary: the investigation is devoted to the study of the effect of the introduction of autologous platelet-rich plasma (prp) on the thickness of the endometrium. it was found that the injection of prp and endometrial cells resuspended in prp into the endometrium of patients with thin endometrium leads to an increase in the proliferation of endometrial cells, and as a result, to an increase in its thickness.

the study enrolled 115 patients with thin endometrium (\<7 mm at implantation window) and infertility. the cohort was divided into groups based on the treatment regimen. group 1 (the control, n=30) underwent conservative therapy. group 2 (n=42) received intraendometrial injections of autologous prp instead of the conservative therapy. group 3 (n=38) received identical injections after conservative therapy. group 4 (n=5) received injections of the minimally manipulated autologous endometrial cells suspended in autologous prp. injections of prp and endometrial cells suspended in autologous prp into basal layer of endometrium facilitate the reconstitution by enhancing cell proliferation and angiogenesis.

Eligibility criteria:
inclusion criteria: * age 18-40 years * normal karyotype * normal karyotype of the partner * regular ovulatory and menstrual cycle * endometrium \<7 mm thick as measured at implantation window * availability of ≥2 vitrified blastocysts of good quality * history of implantation failure and/or embryo transfer (et) cancellation due to insufficient endometrial thickness exclusion criteria: * pathospermia in partner * use of donor gametes * premature ovarian failure * internal genital anomalies * systemic blood diseases and coagulopathy * hemoglobin \<100 g/l * platelets \<100×109/l * antiplatelet/anticoagulant therapy recipient status

Keywords: platelet-rich plasma infertility endometrial cells
olmesartan medoxomil versus losartan in elderly and very elderly

Conditions: Essential Hypertension

Summary: to assess the efficacy of individually optimized doses of olmesartan medoxomil compared to losartan in elderly and very elderly patients with essential hypertension. the study hypothesis is non-inferiority of olmesartan medoxomil compared to losartan in lowering mean sitting diastolic blood pressure after 12 weeks of treatment compared to baseline. the study duration is up to 60 weeks, including a 52-week treatment period. after 12 weeks of treatment hydrochlorothiazide may be added to control blood pressure. efficacy and safety measurements are carried out at up to 18 visits during the trial.


Eligibility criteria:
inclusion criteria: * age 65 years or older * mean sitting diastolic bp = 100-114 mmhg and mean sitting systolic bp \>=150 mm hg exclusion criteria: * secondary hypertension * malignant hypertension * severe heart failure (nyha iii-iv) * history or evidence of renal disease * recent history of myocardial infarction * hypersensitivity to study drugs * history of drug or alcohol abuse
iron supplementation in inflammatory bowel disease (ibd) patients with chronic fatigue

Conditions: Chronic Fatigue; Inflammatory Bowel Disease

Summary: a phase 2, randomized, placebo controlled trial evaluating the effects of n intravenous iron supplementation on chronic fatigue in ibd patients with controlled disease.

the study will evaluate a 6 months therapy with intravenous ferric carboxymaltose. patients will undergo a 2-5 days screening period and then will be treated every 4 weeks with iron supplementation/placebo. at every visit, hematology and blood iron levels will be evaluated. treatment will be temporarily stopped in case of either hemoglobin levels above 16 g/dl or ferritin above 800 ng/ml (level decreased to 500 ng/ml in case of transferrin-iron saturation percentage above 50%). study team will be composed of blinded and unblinded personnel and dedicated infusion devices will be used to ensure the double blinding.

Eligibility criteria:
inclusion criteria: * diagnosis of ulcerative colitis or crohn's disease established at least 6 months prior to day 1 by endoscopy and/or imaging * at least 6 months of clinical remission (harvey bradshaw index ≤5; mayo clinical score ≤ 2) * therapy with mesalamine, immunosuppressors or anti-tumor necrosis factor alpha (tnfα) at stable doses for at least 3 months prior enrollment; steroids are not permitted from 6 months prior baseline * chronic fatigue symptoms (mfi-20\>13) * iron deficiency: ferritin \< 100 microg/l or \< 300 microg/l in case of transferrin-iron saturation percentage (tsat) \<20% * women of childbearing potential must have a negative serum pregnancy test before enrollment. * able and willing to provide written informed consent exclusion criteria: * known hypersensibility to active principle or excipients * pregnant or lactating women * clinically active ibd (harvey bradshaw index \>6; mayo clinical score \>3 or c-reactive protein \>2.5 mg/l * renal failure (egfr\<60) * history of adrenal insufficiency * history of autoimmune diseases * history of malignancies * depression * any current or recent signs or symptoms of viral infectious diseases * recent psycho-traumatic events * hemoglobin levels \< 12.5 g/dl (men) or \<11.5 g/dl (women)

Keywords: iron fatigue crohn's disease ulcerative colitis ibd
cpp-acpf and laser's effect on dentin hypersensitivity

Conditions: Dentin Sensitivity

Summary: the aim of this study was to evaluate the effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (cpp-acpf) associated with low level laser therapy (lllt) in the symptomatology and on the quality of life of the individuals with dentin hypersensitivity in a randomized placebo-controlled clinical trial. volunteers 18 to 50 years old with hypersensitive teeth were randomized into 4 groups: gplacebo - positioning of the laser tip without light emission + placebo dentifrice; gcppacpf - positioning of the laser tip without light emission + cpp-acpf application; glaser - laser tip positioning with light emission + placebo dentifrice; glasercppacpf - positioning and light emission of the laser beam + cpp-acpf.

glaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active asgaal medium in two points of the vestibular face of the hypersensitive teeth. at each point it was applied 60 j / cm², for 16 seconds. three laser's sessions were applied with a time interval of 24 hours between them. glasercppacpf first received the cppacpf application and then the laser application according to the manufacturer's recommendations. before initiating laser therapy, the equipment was calibrated with a tester (mmoptics ltda®, brazil). the gcppacpf volunteers were submitted to the application of the cppacpf's containing tooth paste mi paste plus™ (recaldent™, gc américa, usa) on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (microbrush, 3m espe, brazil) for 05 minutes. then, a rubber cup (unid microdont, brazil) mounted on a low speed handpiece (500, kavo, germany) was used to scrub the desensitizing gel during 20 seconds on each tooth, according to the manufacturer's specifications. gplacebo followed the same protocol used in gcppacpf. in addition to the desensitizing treatments, all gcppacpf and gplacebo volunteers received the positioning of the laser tip to mimic the light emission produced in glaser and glasercppacpf. the noise emitted by the laser device was mimic through the sound reproduction of a smartphone application (hd voice recorder - iphone 6s, apple®, usa).

Eligibility criteria:
inclusion criteria: * the presence of at least two hypersensitive teeth; exclusion criteria: * milk's proteins allergy; * systemic diseases; * teeth with carious lesions or pulpitis; * teeth with defective restorations; * teeth with with cleft enamel; * patients with active periodontal disease; * patients with analgesic medication; * patients with pregnant or lactating women * patients who have received professional desensitizing treatment in the last three months.

Keywords: desensitizing treatment dental hypersensitivity cppacpf low level laser therapy
adjuvant chemoradiation following radical resection of pancreatic ductal adenocarcinoma, a prospective cohort study

Conditions: Resectable Pancreatic Cancer; Adjuvant Chemoradiotherapy; Surgery

Summary: this is a prospective observation cohort study to evaluate efficacy of different types of adjuvant therapy strategies, including chemoradiotherapy, chemotherapy alone, or no adjuvant treatment, for pancreatic ductal adenocarcinoma patients who received surgical resection of primary cancer.


Eligibility criteria:
inclusion criteria: 1. age between 18 to 90 years. 2. received surgical resection of primary tumor. 3. histological diagnosis of pancreatic ductal adenocarcinoma. 4. signed informed consent. exclusion criteria: 1.active concomitant malignancy (malignancy other than pancreatic cancer).
the role of antibiotics in full thickness skin graft survival for facial reconstructive surgery

Conditions: Facial Defect

Summary: antibiotics are sometimes prescribed to patients who have had reconstructive surgery of wounds on their face using skin grafts. but, it is not yet known whether antibiotics improve the healing of skin grafts and reduce the risk of infections after surgery in these patients. it is known that antibiotics, like all medications, have side-effects although these are rare. this research study is designed to show us whether antibiotics improve wound healing or not, so that we may determine if we should continue using antibiotics even if they have side-effects in some patients. our hypothesis is that patients treated with post-operative, systemic antibiotics will demonstrate a statistically significant improvement in the survival of their facial full thickness skin grafts compared to patients who are not treated with systemic antibiotics.


Eligibility criteria:
inclusion criteria: * all adult patients with a nasal or facial skin/soft tissue defect requiring reconstruction limited to or including a full-thickness skin graft exclusion criteria: * current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect.

Keywords: facial skin wound facial wound skin wound facial defect reconstructive skin graft
definition of biomechanical indices measurable during sport movements for the prevention of primary and secondary acl injury

Conditions: Sport Injury; Anterior Cruciate Ligament Injury; Biomechanical; Lesion

Summary: the aim of the study is to define a set of quantitative parameters related to articular biomechanics, which will be evaluated during some specific motor tasks. the goal is the prevention of primary and secondary anterior cruciate ligament injury in athletes. specifically, the validation of a new comparative methodology of biomechanics analysis will be performed, based on inertial sensors and musculoskeletal models. this way, brief but exhaustive description of functional characteristics of athletes could be created and easily used in ambulatory environment.


Eligibility criteria:
inclusion criteria: * healthy subjects, men of women, 18 years old minimum and 50 maximum, which read and signed the informed consent exclusion criteria: * evidence of any kind of musculoskeletal disease or impairment * evidence of past surgical intervention to either lower or upper limbs * age out of the inclusion range * cardiac or pulmonary diseases * inability to read and sign the informed consent * inability to perform the motor tasks required

Keywords: injury prevention biomechanical indices inertial sensors
safety and efficacy of remote ischemic conditioning for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

in this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in china according to the principle of random, and parallel control. the experimental group receive basic treatment and remote ischemic conditioning for 200mmhg, 2 times per day for 7 consecutive days. the control group receive basic treatment and remote ischemic conditioning control for 60mmhg, 2 times per day for 7 consecutive days. two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * 1) age≥18 years, regardless of sex. * 2) patients with clinically definite diagnosis of acute ischemic stroke and able to commence ric treatment within 72 hours of stroke onset. * 3) baseline nihss ≥ 4, ≤ 24. * 4) baseline mrs ≤ 2; * 5) signed and dated informed consent is obtained. exclusion criteria: * 1) patients who undergo thrombolytic therapy or endovascular treatment. * 2) the patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc. * 3) other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain. * 4) pregnant or lactating women. * 5) previous remote ischemic conditioning therapy or similar treatment. * 6) severe hepatic and renal dysfunction. * 7) patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons. * 8) unwilling to be followed up or treated for poor compliance. * 9) he/she is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission. * 10) other conditions that the researchers think are not suitable for the group.
comparison of treatment outcome and cost-effectiveness for gerd

Conditions: Gastroesophageal Reflux

Summary: this study was designed to evaluate the effectiveness of laparoscopic antireflux surgery for treatment of gastroesophageal reflux disease (gerd) comparing with that of non-surgical treatment.

to treat gerd, the most patients with gerd are managed with acid suppressive medication first, and followed by antireflux surgery when the medical therapy is not effective or when the patient prefer surgery to quit the medicine. this study has a single cohort in which the patient has the past history of gerd and medical treatment with proton pump inhibitors, and has scheduled to have laparoscopic antireflux surgery for treatment of gerd. treatment outcome of surgery will be evaluated comparing with the outcome of medical treatment before registration.

Eligibility criteria:
inclusion criteria: * objectively diagnosed gerd * past history of medical treatment with ppi more than 8 weeks at any time before antireflux surgery * patients scheduled to undergo antireflux surgery to treat gerd exclusion criteria: * other pathologic condition in upper gastrointestinal tract which needs surgical treatment * no (or less than 8 weeks) past history of acid suppressive medical therapy with ppi * patients who underwent endoscopic antireflux procedure

Keywords: gastroesophageal reflux disease antireflux surgery
influence of n-acetylcysteine maintenance on alcohol effects

Conditions: Alcohol Use Disorder

Summary: this study will evaluate the behavioral effects of alcohol during placebo and n-acetylcysteine maintenance using sophisticated human laboratory methods.


Eligibility criteria:
inclusion criteria: * able to speak/read english * not seeking treatment at the time of the study * one binge drinking episode (5+/4+ standard alcoholic drinks per drinking session for men and women, respectively) in the past 30 days * recent alcohol use verified by ethyl glucuronide positive urine, as well as fulfillment of dsm-5 diagnostic criteria for alcohol use disorder * ecg within normal limits * otherwise healthy * body mass index of 19-35 * females using an effective form of birth control and not pregnant or breast feeding * judged by the medical staff to be psychiatrically and physically healthy * able to abstain from alcohol for 12 hours prior to session * no contraindications/allergies to n-acetylcysteine
exercise in peripheral artery disease

Conditions: Peripheral Artery Disease; Intermittent Claudication

Summary: this research project aims to investigate the gender-based difference in patients with peripheral artery disease. to attend this, this study has two specific objectives: objective 1: to identify gender-specific barriers towards exercise and physical activity in patients with peripheral artery disease (pad). objective 2: to evaluate gender-specific differences in functional capacity and cardiovascular function and regulation in patients with pad at rest, during and following a single session of maximal exercise.


Eligibility criteria:
inclusion criteria: * ankle-brachial index (abi) ≤ 0.9 in one or two legs * fontaine stage ii of pad * body mass index \<35 kg/m2 * resting systolic blood pressure (bp) \<160 mmhg and diastolic bp \<105 mmhg * ability to walk at least 2min at 3.2 km/h * ability to undertake an incremental treadmill test * decrease of at least 15% in abi after a maximal treadmill test * not currently engaging in any regular exercise program exclusion criteria: * exercise induced signs of myocardial ischemia or complex ventricular arrhythmias * cardiovascular autonomic neuropathy * use of beta-blocker * nondihydropyridine calcium antagonists or insulin and hormone replacement therapy
do educational digital films enhance patient copd outcomes?

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study aims to assess the efficacy of pocket medic to promote self-management and pulmonary rehabilitation adherence in copd patients.

chronic obstructive pulmonary disease (copd) refers to a group of lung conditions characterized by airways inflammation, small airways obstruction and progressive loss of lung function. there are 900,000 people diagnosed with copd in england and wales but allowing for under-diagnosis, the true prevalence could be 1.5 million. sufferers are extensive health care users; where copd is the second most common cause of emergency hospital admission in the united kingdom with direct national health service costs over £800 million per year. pulmonary rehabilitation programs (prps) aim to provide education and support for patients whilst improving clinical outcomes, however, attendance to these programs can be low. this study aims to trial a series of digital films aimed at educating patients about their condition from the comfort of their own home. approximately 80 patients eligible for pr will be allocated to an experimental condition to receive a series of 10 digital films alongside their standard 7-week pr, solely to receive 10 digital films, or to a control condition in the form of standard pr (no digital films). outcome measures such as pr attendance, hospital admissions, quality of life (qol), disease knowledge, psychological need satisfaction and motivation will be measured pre and post. analysis of this data between the experimental and control conditions pre-post intervention will provide useful information regarding the efficacy of digital film prescriptions as an adjunct to usual pr, or on its own, and the role this may play is encouraging pr attendance.

Eligibility criteria:
inclusion criteria: * eligible for pulmonary rehabilitation in hywel dda university health board. exclusion criteria: * unwilling or unable to give informed consent * life expectancy of less than 6 months * unstable cardiovascular disease, dementia, cancers other than non-melanoma skins cancer * any condition that precludes patients using laptops or mobile phones (e.g. blind, deaf)
transgene assay testing service of tumor samples from patients who received a bristol-myers squibb manufactured gene modified cell therapy and have a qualifying second primary malignancy

Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukaemia; Multiple Myeloma

Summary: the purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available bristol-myers squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.


Eligibility criteria:
inclusion criteria: * participant has received a commercially available bristol-myers squibb (bms) manufactured gene modified cell therapy (gmct) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which bms has qualified for testing. * participant has received a commercially available bms manufactured gmct in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which bms has qualified for testing. exclusion criteria: * participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial. * participant has not received a bms manufactured gmct or has not been diagnosed with a qualifying second primary malignancy.